The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...

CINCINNATI (WKRC) - A medication previously available only for adults is now on the market for children to help reduce migraines. Recent research focused on children aged six to 17 and examined a ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...

Teva Pharmaceutical (NYSE:TEVA) announced on Wednesday that the U.S. Food and Drug Administration (FDA) approved its migraine therapy Ajovy for children and adolescents, expanding its previous label ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...

SAN DIEGO -- Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE trial. The phase III study showed a reduction in monthly migraine ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U ...

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Teva Pharmaceutical Industries Limited is one of them. Teva Pharmaceutical Industries Limited (NYSE:TEVA) tops our list ...